Why Halozyme Therapeutics Is Trading 14% Higher Today

Why Halozyme Therapeutics Is Trading 14% Higher Today
Eric Volkman, The Motley Fool
·2 min read

Halozyme Therapeutics (NASDAQ: HALO) was well in double-digit territory on Wednesday, as its stock was up by over 14% in mid-afternoon trading. For its fourth quarter of 2020, Halozyme earned $121.7 million in revenue, more than double the $53.7 million of the year-ago quarter. Fueled by royalty payments that are expected to roughly double, revenue should come in at $375 million to $395 million for 2021 -- meaning at least a 40% improvement over the 2020 tally.